Insulet (PODD) Stock

Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.

Insulet's Omnipod 5 System can now work with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.

Insulet's stock has increased by over 50% in the last six months, thanks to strong earnings in the third quarter and the approval of Omnipod 5 for Type 2 diabetes, which opens up new market opportunities. However, the company faces challenges from high market expectations and competition from major players like Medtronic and Abbott, which could impact its future success. While Insulet's financial situation is strong, with growing revenues and profits, the high stock price requires ongoing impressive growth to justify it.

Insulet Corporation, known for its Omnipod® tubeless insulin pump technology, has announced that its management will speak at three investor conferences. These events include the 6th Annual Wolfe Research Healthcare Conference in New York City on November 20, 2024, and the Nasdaq 51st Investor Conference in London on December 10, 2024.

Jim Hollingshead, the CEO of Insulet, appears on 'Closing Bell: Overtime' to talk about the company's earnings, the Apple app for blood sugar testing, and other topics.

Insulet Corporation (PODD) has released the transcript for their Q3 2024 earnings call.

Insulet (PODD) reported quarterly earnings of $0.90 per share, which is higher than the Zacks Consensus Estimate of $0.77 per share. This is an increase compared to earnings of $0.71 per share from the same period last year.

On Thursday, Insulet increased its forecast for annual revenue growth, expecting high demand for its wearable insulin pumps.

PODD is working to raise awareness of Omnipod by running a direct-to-consumer advertising campaign.